- Repros (NASDAQ:RPRX) will host a conference call today at 5:00 pm ET to discuss its recent meeting with the FDA concerning the development of enclomiphene citrate for the treatment of men with low testosterone due to secondary hypogonadism.
- In early December, the company received a Complete Response Letter (CRL) in response to its NDA citing the need for more supporting data.
- Previously: Repros receives CRL from FDA regarding enclomiphene citrate NDA; shares slump 33% (Dec. 1, 2015)
Repros to update investors on meeting with FDA to discuss enclomiphene development
Recommended For You
About RPRX Stock
Related Stocks
| Symbol | Last Price | % Chg |
|---|---|---|
| RPRX | - | - |
| Royalty Pharma plc | ||